Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (EBRDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (EBRDA) has a cash flow conversion efficiency ratio of -2.079x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-53.19 Million) by net assets (AU$25.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cdi 10:1 Us Prohib Excl Qib Deferred Settlement ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Miton UK MicroCap Trust PLC
LSE:MINI
|
-0.004x |
|
Fantasy Network Ltd
TA:FNTS
|
-0.069x |
|
Man Shing Agricultural Holdings Inc
PINK:MSAH
|
0.055x |
|
Petrovietnam Pac
VN:PBP
|
N/A |
|
Cuulong Fish JSC
VN:ACL
|
N/A |
|
National Silk and Rayon Mills Limited
KAR:NSRM
|
N/A |
|
MEGA AFRICAN CAPITAL LIMITED
GSE:MAC
|
N/A |
|
Canyon Bancorp
PINK:CYBA
|
N/A |
Annual Cash Flow Conversion Efficiency for Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (2023–2025)
The table below shows the annual cash flow conversion efficiency of Cdi 10:1 Us Prohib Excl Qib Deferred Settlement from 2023 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | AU$25.59 Million | AU$-53.19 Million | -2.079x | -22.80% |
| 2024-12-31 | AU$24.36 Million | AU$-41.23 Million | -1.693x | -60.79% |
| 2023-12-31 | AU$31.06 Million | AU$-32.70 Million | -1.053x | -- |
About Cdi 10:1 Us Prohib Excl Qib Deferred Settlement
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization thera… Read more